Needham & Company Downgrades Sarepta Therapeutic (SRPT) to Hold
Tweet Send to a Friend
Needham & Company downgraded Sarepta Therapeutic (NASDAQ: SRPT) from Buy to Hold after the FDA issued a major set back ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE